In an attempt to further diversify its pipeline, Neurocrine BioSciences has agreed to pay US$100 M upfront and committed up to US$2.6 B more to access Sosei Heptares’ subtype specific muscarinic agonists. These candidates are potential treatments for various neurological diseases which have proven exceptionally difficult to treat, such as schizophrenia and dementia. The deal comes shortly after Neurocrine’s schizophrenia candidate, licensed from Takeda, failed its Phase II clinical trial.